enGene Therapeutics Inc. Common Stock Share Price
NASDAQ: ENGNHealthcare
Live enGene Therapeutics Inc. Common Stock Share Price Chart
O H L
enGene Therapeutics Inc. Common Stock Performance Overview
Days Range
▼
$1.90Low
$1.90High
Markets Today
| Previous Close | $1.91 |
|---|---|
| Open | $1.90 |
| Volume | 55,423 |
| Day's Range | $1.90 - $1.90 |
| 52W Range | $1.40 - $12.25 |
| Market Cap | $128.00 M |
Historical Performance
| 1M Returns | +11.05 |
|---|---|
| 3M Returns | +11.05 |
| 6M Returns | -73.40 |
| 1Y Returns | -72.56 |
| 5Y Returns | NA |
| 10Y Returns | NA |
enGene Therapeutics Inc. Common Stock Fundamentals
| Market Cap | $128.00 M |
|---|---|
| Dividend yield | 0.00 |
| PE Ratio | 0.00 |
| PEG Ratio | N/A |
| Revenue | $0.00 |
| ROE TTM | -0.53 |
| EPS TTM | $-2.08 |
| Quarterly Earnings Growth YOY | N/A |
| PB Ratio | 0.56 |
| EBITDA | $-122.66 M |
| Profit Margin | N/A |
| Market Cap | $128.00 M |
|---|---|
| Dividend yield | 0.00 |
| PE Ratio | 0.00 |
| PEG Ratio | N/A |
| Revenue | $0.00 |
| ROE TTM | -0.53 |
| EPS TTM | $-2.08 |
|---|---|
| Quarterly Earnings Growth YOY | N/A |
| PB Ratio | 0.56 |
| EBITDA | $-122.66 M |
| Profit Margin | N/A |
enGene Therapeutics Inc. Common Stock Profit & Loss
Quarterly
| Apr 2025 | Jul 2025 | Oct 2025 | Jan 2026 | Apr 2026 | Jul 2026 | |
|---|---|---|---|---|---|---|
| Total Revenue + | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit + | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$27.12 M | -$29.95 M | -$39.48 M | -$31.18 M | -$31.97 M | -$34.01 M |
| EBITDA | -$27.02 M | -$29.82 M | -$39.31 M | -$31.00 M | -$31.79 M | -$33.84 M |
| Interest Expense | -$734.00 K | -$758.00 K | -$750.00 K | -$732.00 K | -$745.00 K | -$843.00 K |
| Depreciation | $106.00 K | $130.00 K | $171.00 K | $189.00 K | $180.00 K | $178.00 K |
| Income Before Tax | -$25.57 M | -$28.75 M | -$38.38 M | -$29.75 M | -$30.23 M | -$32.50 M |
| Income Tax Expense | $240.00 K | $239.00 K | -$497.00 K | $0 | $0 | $0 |
| Net Income + | -$25.82 M | -$28.99 M | -$37.88 M | -$29.75 M | -$30.23 M | -$32.50 M |
| Net Profit Margin | - | - | - | - | - | - |
enGene Therapeutics Inc. Common Stock Financials Balance Sheet In USD
Quarterly
| Apr 2025 | Jul 2025 | Oct 2025 | Jan 2026 | Apr 2026 | Jul 2026 | |
|---|---|---|---|---|---|---|
| Share Capital | $510.12 M | $510.16 M | $513.28 M | $631.99 M | $632.00 M | $632.02 M |
| Reserve & Surplus | -$306.13 M | -$335.36 M | -$372.92 M | -$402.63 M | -$433.15 M | -$465.86 M |
| Non-Current Liabilities | $21.36 M | $24.44 M | $21.78 M | $30.96 M | $30.87 M | $30.82 M |
| Current Liabilities | $18.00 M | $20.44 M | $31.98 M | $24.61 M | $21.48 M | $27.21 M |
| Total Liabilities | $39.36 M | $44.88 M | $53.76 M | $55.57 M | $52.36 M | $58.03 M |
| Fixed Assets | $1.55 M | $1.88 M | $2.48 M | $2.44 M | $2.33 M | $2.16 M |
| Current Assets | $227.97 M | $211.31 M | $201.39 M | $289.22 M | $270.00 M | $277.90 M |
| Total Assets | $266.65 M | $245.55 M | $221.47 M | $337.11 M | $307.52 M | $288.32 M |
enGene Therapeutics Inc. Common Stock Cash Flow
Quarterly
| Apr 2025 | Jul 2025 | Oct 2025 | Jan 2026 | Apr 2026 | Jul 2026 | |
|---|---|---|---|---|---|---|
| Net Income | -$25.82 M | -$28.99 M | -$37.88 M | -$29.75 M | -$30.23 M | -$32.50 M |
| Operating Cash Flow | -$22.95 M | -$25.63 M | -$24.96 M | -$28.90 M | -$30.50 M | -$18.95 M |
| Investing Cash Flow | $17.95 M | $1.38 M | $40.50 M | -$126.30 M | $23.64 M | $30.12 M |
| Financing Cash Flow | $199.00 K | -$667.00 K | $1.99 M | $141.66 M | $74.00 K | $23.00 K |
| Change in Cash | -$4.80 M | -$24.92 M | $17.53 M | -$13.54 M | -$6.79 M | $11.20 M |
enGene Therapeutics Inc. Common Stock Return Calculator
The enGene Therapeutics Inc. Common Stock stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.
Returns Estimator
Based on past performance of this fund
ENTER AMOUNT
$10,000
Select Duration
5Yrs
1 Yr5 Yrs
If you had invested $10,000 5 years ago, what would its value be today?$10,000
Invested Amount$10,000
Est. Returns$0
About enGene Therapeutics Inc. Common Stock
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
Popular Stocks
FAQs
What is the share price of enGene Therapeutics Inc. Common Stock today?
enGene Therapeutics Inc. Common Stock (ENGN) share price as of September 18, 2026 is $1.90. If you are investing from India, you can always check the valuation in the INR before investing.
Can Indian Investors purchase shares of enGene Therapeutics Inc. Common Stock?
Yes, Indian Investors can invest in the enGene Therapeutics Inc. Common Stock (ENGN) Share by opening an international trading account with Angel One.
How can I purchase enGene Therapeutics Inc. Common Stock shares in India?
Purchasing enGene Therapeutics Inc. Common Stock (ENGN) share from India can be done by: Directly: By opening an international trading account with Angel One. The process would include KYC verification. The account activation takes a few minutes to a few hours, after which you can start buying enGene Therapeutics Inc. Common Stock (ENGN) by making deposits in US dollars. Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.
Can I buy Fractional shares of enGene Therapeutics Inc. Common Stock?
Yes, you can purchase fractional shares of enGene Therapeutics Inc. Common Stock (ENGN) or any other US company shares in Angel One for any dollar amount.
What is the market capitalization value of enGene Therapeutics Inc. Common Stock?
The market capitalization of enGene Therapeutics Inc. Common Stock on September 18, 2026, is $128.00 M.
In which sector enGene Therapeutics Inc. Common Stock belongs?
enGene Therapeutics Inc. Common Stock operates in the Healthcare sector, specifically in the Healthcare industry.
What documents are required to invest in enGene Therapeutics Inc. Common Stock stocks?
In order to invest in enGene Therapeutics Inc. Common Stock (ENGN) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.). From start to end, the process is digital and can be seamless.
Diversify Your Portfolio with US Stocks
Invest in Wall Street Giants from India
